Kymera Therapeutics Intrinsic Value – KYMERA THERAPEUTICS Reports 43.4% Year-Over-Year Increase in Total Revenue for Q2 of Fiscal Year 2023
August 27, 2023
☀️Earnings Overview
KYMERA THERAPEUTICS ($NASDAQ:KYMR) announced their financial performance for the second quarter of Fiscal Year 2023 on August 3 2023. Total revenue for the quarter amounted to USD 16.5 million, a 43.4% increase from the same period in the prior year. Net income for the quarter was reported as USD -38.8 million, a decrease from the previous year’s figure of -40.3 million.
Analysis – Kymera Therapeutics Intrinsic Value
GoodWhale has conducted an in-depth analysis of KYMERA THERAPEUTICS‘ well-being and the value of its stock. According to our proprietary Valuation Line, the fair value of a KYMERA THERAPEUTICS share stands at $34.3. However, the company’s stock is currently trading at $23.9, which implies that it is undervalued by 30.3%. This presents an opportunity for investors looking for a good deal on their investments. With this in mind, we believe that KYMERA THERAPEUTICS is a great buy at its current price. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Kymera Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 51.67 | -157.59 | -305.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Kymera Therapeutics. More…
| Operations | Investing | Financing |
| -153.03 | -26.72 | 154.91 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Kymera Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 581.95 | 146.52 | 7.86 |
Key Ratios Snapshot
Some of the financial key ratios for Kymera Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 75.9% | – | -304.6% |
| FCF Margin | ROE | ROA |
| -327.9% | -21.9% | -16.9% |
Peers
The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.
– Abionyx Pharma ($LTS:0RAG)
Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.
– Shattuck Labs Inc ($NASDAQ:STTK)
Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.
– Prestige BioPharma Ltd ($KOSE:950210)
Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).
Summary
Investors in KYMERA THERAPEUTICS were pleased to learn that for the second quarter of Fiscal Year 2023, the company reported total revenue of USD 16.5 million, a 43.4% year-over-year increase. The positive news caused the stock price to go up on August 3 2023, indicating that investors are optimistic about the company’s performance. This is a positive sign for KYMERA THERAPEUTICS, as they strive to maintain their growth trajectory.
Related Posts
Recent Posts
